Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

Cancer Cell

Volumn 26, Issue 5, 2014, Pages 605-622

  Jain, Rakesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL; CANCER SURVIVAL; CANCER THERAPY; ENDOTHELIUM CELL; HUMAN; HYPOXIA; IMMUNOTHERAPY; NONHUMAN; OXYGENATION; SOLID TUMOR; VASCULARIZATION; ANIMAL; CELL HYPOXIA; DRUG POTENTIATION; DRUG RESISTANCE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84912096468     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.10.006     Document Type: Review

References (180)

1. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J.Clin. Invest. 2003, 112:1142-1151.
2. Aguilera K.Y., Rivera L.B., Hur H., Carbon J.G., Toombs J.E., Goldstein C.D., Dellinger M.T., Castrillon D.H., Brekken R.A. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res. 2014, 74:1032-1044.
3. Arjaans M., Oude Munnink T.H., Oosting S.F., Terwisscha van Scheltinga A.G., Gietema J.A., Garbacik E.T., Timmer-Bosscha H., Lub-de Hooge M.N., Schröder C.P., de Vries E.G. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res. 2013, 73:3347-3355.
4. Barsoum I.B., Smallwood C.A., Siemens D.R., Graham C.H. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014, 74:665-674.
5. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
6. Batchelor T.T., Gerstner E.R., Emblem K.E., Duda D.G., Kalpathy-Cramer J., Snuderl M., Ancukiewicz M., Polaskova P., Pinho M.C., Jennings D., et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc. Natl. Acad. Sci. USA 2013, 110:19059-19064.
7. Bindra R.S., Crosby M.E., Glazer P.M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007, 26:249-260.
8. Bottos A., Martini M., Di Nicolantonio F., Comunanza V., Maione F., Minassi A., Appendino G., Bussolino F., Bardelli A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc. Natl. Acad. Sci. USA 2012, 109:E353-E359.
9. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 2008, 8:180-192.
10. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., Rugo H.S. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J.Clin. Oncol. 2011, 29:4286-4293.
11. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 2010, 10:138-146.
12. Calcinotto A., Filipazzi P., Grioni M., Iero M., De Milito A., Ricupito A., Cova A., Canese R., Jachetti E., Rossetti M., et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012, 72:2746-2756.
13. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
14. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
15. Casazza A., Di Conza G., Wenes M., Finisguerra V., Deschoemaeker S., Mazzone M. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 2014, 33:1743-1754.
16. Castets M., Mehlen P. Netrin-1 role in angiogenesis: to be or not to be a pro-angiogenic factor?. Cell Cycle 2010, 9:1466-1471.
17. Chauhan V.P., Stylianopoulos T., Martin J.D., Popović Z., Chen O., Kamoun W.S., Bawendi M.G., Fukumura D., Jain R.K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 2012, 7:383-388.
18. Chauhan V.P., Martin J.D., Liu H., Lacorre D.A., Jain S.R., Kozin S.V., Stylianopoulos T., Mousa A.S., Han X., Adstamongkonkul P., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 2013, 4:2516.
19. Chauhan V.P., Boucher Y., Ferrone C.R., Roberge S., Martin J.D., Stylianopoulos T., Bardeesy N., DePinho R.A., Padera T.P., Munn L.L., Jain R.K. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 2014, 26:14-15.
20. Chen Y., Huang Y., Reiberger T., Duyverman A.M., Huang P., Samuel R., Hiddingh L., Roberge S., Koppel C., Lauwers G.Y., et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice. Hepatology 2014, 59:1435-1447.
21. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34.
22. Chiang H.Y., Korshunov V.A., Serour A., Shi F., Sottile J. Fibronectin is an important regulator of flow-induced vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1074-1079.
23. Chung A.S., Kowanetz M., Wu X., Zhuang G., Ngu H., Finkle D., Komuves L., Peale F., Ferrara N. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J.Pathol. 2012, 227:404-416.
24. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.-M., Jiang Z., Meng Y.G., Peale F.V., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114-1123.
25. Colegio O.R., Chu N.Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., Cyrus N., Brokowski C.E., Eisenbarth S.C., Phillips G.M., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513:559-563.
26. De Bock K., Georgiadou M., Carmeliet P. Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 2013, 18:634-647.
27. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
28. di Tomaso E., London N., Fuja D., Logie J., Tyrrell J.A., Kamoun W., Munn L.L., Jain R.K. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS ONE 2009, 4:e5123.
29. Duda D.G., Willett C.G., Ancukiewicz M., di Tomaso E., Shah M., Czito B.G., Bentley R., Poleski M., Lauwers G.Y., Carroll M., et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010, 15:577-583.
30. Duda D.G., Kozin S.V., Kirkpatrick N.D., Xu L., Fukumura D., Jain R.K. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin. Cancer Res. 2011, 17:2074-2080.
31. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J.Clin. Oncol. 2002, 20:4368-4380.
32. Elisei R., Schlumberger M.J., Müller S.P., Schöffski P., Brose M.S., Shah M.H., Licitra L., Jarzab B., Medvedev V., Kreissl M.C., et al. Cabozantinib in progressive medullary thyroid cancer. J.Clin. Oncol. 2013, 31:3639-3646.
33. Emblem K.E., Mouridsen K., Bjornerud A., Farrar C.T., Jennings D., Borra R.J., Wen P.Y., Ivy P., Batchelor T.T., Rosen B.R., et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat. Med. 2013, 19:1178-1183.
34. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N.Engl. J. Med. 2007, 356:125-134. TARGET Study Group.
35. Escudier B., Bellmunt J., Négrier S., Bajetta E., Melichar B., Bracarda S., Ravaud A., Golding S., Jethwa S., Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J.Clin. Oncol. 2010, 28:2144-2150.
36. Falchook G.S., Moulder S.L., Wheler J.J., Jiang Y., Bastida C.C., Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann. Oncol. 2013, 24:3004-3011.
37. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M.A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA 2000, 97:3884-3889.
38. Farsaci B., Higgins J.P., Hodge J.W. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int. J. Cancer 2012, 130:1948-1959.
39. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2:795-803.
40. Finger E.C., Giaccia A.J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010, 29:285-293.
41. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
42. Folkman J. Tumor angiogenesis: therapeutic implications. N.Engl. J. Med. 1971, 285:1182-1186.
43. Foy K.C., Miller M.J., Moldovan N., Carson Iii W.E., Kaumaya P.T.P. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects invitro and invivo. OncoImmunology 2012, 1:1048-1060.
44. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 2011, 11:135-141.
45. Fuchs C.S., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C., Safran H., dos Santos L.V., Aprile G., Ferry D.R., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383:31-39. REGARD Trial Investigators.
46. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6:521-534.
47. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 1999, 5:2963-2970.
48. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
49. Gianni L., Romieu G.H., Lichinitser M., Serrano S.V., Mansutti M., Pivot X., Mariani P., Andre F., Chan A., Lipatov O., et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J.Clin. Oncol. 2013, 31:1719-1725.
50. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., Benson A.B. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J.Clin. Oncol. 2007, 25:1539-1544. Eastern Cooperative Oncology Group Study E3200.
51. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat. Rev. Cancer 2013, 13:871-882.
52. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
53. Goel S., Fukumura D., Jain R.K. Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology. Proc. Natl. Acad. Sci. USA 2012, 109:E1214.
54. Goel S., Gupta N., Walcott B.P., Snuderl M., Kesler C.T., Kirkpatrick N.D., Heishi T., Huang Y., Martin J.D., Ager E., et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J.Natl. Cancer Inst. 2013, 105:1188-1201.
55. Goveia J., Stapor P., Carmeliet P. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol. Med. 2014, 6:1105-1120.
56. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., Humblet Y., Bouché O., Mineur L., Barone C., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312. CORRECT Study Group.
57. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Gröne H.J., Hämmerling G.J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
58. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
59. Hayashi H., Kurata T., Fujisaka Y., Kawakami H., Tanaka K., Okabe T., Takeda M., Satoh T., Yoshida K., Tsunoda T., et al. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. Cancer Sci. 2013, 104:98-104.
60. Hellström M., Phng L.K., Hofmann J.J., Wallgard E., Coultas L., Lindblom P., Alva J., Nilsson A.K., Karlsson L., Gaiano N., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445:776-780.
61. Heskamp S., Boerman O.C., Molkenboer-Kuenen J.D.M., Oyen W.J.G., van der Graaf W.T.A., van Laarhoven H.W.M. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int. J. Cancer 2013, 133:307-314.
62. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95:4607-4612.
63. Hodi F.S., Lawrence D., Lezcano C., Wu X., Zhou J., Sasada T., Zeng W., Giobbie-Hurder A., Atkins M.B., Ibrahim N., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014, 2:632-642.
64. Huang X., Wong M.K., Yi H., Watkins S., Laird A.D., Wolf S.F., Gorelik E. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res. 2002, 62:5727-5735.
65. Huang H., Bhat A., Woodnutt G., Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 2010, 10:575-585.
66. Huang Y., Yuan J., Righi E., Kamoun W.S., Ancukiewicz M., Nezivar J., Santosuosso M., Martin J.D., Martin M.R., Vianello F., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 2012, 109:17561-17566.
67. Huang Y., Goel S., Duda D.G., Fukumura D., Jain R.K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013, 73:2943-2948.
68. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
69. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 1988, 48:2641-2658.
70. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
71. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
72. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J.Clin. Oncol. 2013, 31:2205-2218.
73. Jain R.K. An indirect way to tame cancer. Sci. Am. 2014, 310:46-53.
74. Jain R.K., Safabakhsh N., Sckell A., Chen Y., Jiang P., Benjamin L., Yuan F., Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 1998, 95:10820-10825.
75. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
76. Jain R.K., Finn A.V., Kolodgie F.D., Gold H.K., Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4:491-502.
77. Jain R.K., Martin J.D., Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 2014, 16:321-346.
78. Jodele S., Chantrain C.F., Blavier L., Lutzko C., Crooks G.M., Shimada H., Coussens L.M., Declerck Y.A. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005, 65:3200-3208.
79. Johansson A., Hamzah J., Payne C.J., Ganss R. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl. Acad. Sci. USA 2012, 109:7841-7846.
80. Karar J., Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 2011, 4:51.
81. Kashiwagi S., Tsukada K., Xu L., Miyazaki J., Kozin S.V., Tyrrell J.A., Sessa W.C., Gerweck L.E., Jain R.K., Fukumura D. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 2008, 14:255-257.
82. Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
83. Keizman D., Huang P., Eisenberger M.A., Pili R., Kim J.J., Antonarakis E.S., Hammers H., Carducci M.A. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur. J. Cancer 2011, 47:1955-1961.
84. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M.F., O'Reilly E., Wozniak T.F., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J.Clin. Oncol. 2010, 28:3617-3622.
85. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., Golshayan A., Rayman P.A., Wood L., Garcia J., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15:2148-2157.
86. Kodack D.P., Chung E., Yamashita H., Incio J., Duyverman A.M., Song Y., Farrar C.T., Huang Y., Ager E., Kamoun W., et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc. Natl. Acad. Sci. USA 2012, 109:E3119-E3127.
87. Kozono S., Ohuchida K., Eguchi D., Ikenaga N., Fujiwara K., Cui L., Mizumoto K., Tanaka M. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 2013, 73:2345-2356.
88. Lambrechts D., Claes B., Delmar P., Reumers J., Mazzone M., Yesilyurt B.T., Devlieger R., Verslype C., Tejpar S., Wildiers H., et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012, 13:724-733.
89. Lambrechts D., Lenz H.J., de Haas S., Carmeliet P., Scherer S.J. Markers of response for the antiangiogenic agent bevacizumab. J.Clin. Oncol. 2013, 31:1219-1230.
90. Lawler P.R., Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012, 2:a006627.
91. Lee K.E., Simon M.C. From stem cells to cancer stem cells: HIF takes the stage. Curr. Opin. Cell Biol. 2012, 24:232-235.
92. Li B., Lalani A.S., Harding T.C., Luan B., Koprivnikar K., Huan Tu G., Prell R., VanRoey M.J., Simmons A.D., Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory Tcells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 2006, 12:6808-6816.
93. Liu J., Liao S., Diop-Frimpong B., Chen W., Goel S., Naxerova K., Ancukiewicz M., Boucher Y., Jain R.K., Xu L. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl. Acad. Sci. USA 2012, 109:16618-16623.
94. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. N.Engl. J. Med. 2008, 359:378-390. SHARP Investigators Study Group.
95. Maes H., Kuchnio A., Peric A., Moens S., Nys K., De Bock K., Quaegebeur A., Schoors S., Georgiadou M., Wouters J., et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014, 26:190-206.
96. Magnussen A., Kasman I.M., Norberg S., Baluk P., Murray R., McDonald D.M. Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res. 2005, 65:2712-2721.
97. Maione F., Molla F., Meda C., Latini R., Zentilin L., Giacca M., Seano G., Serini G., Bussolino F., Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J.Clin. Invest. 2009, 119:3356-3372.
98. Manning E.A., Ullman J.G.M., Leatherman J.M., Asquith J.M., Hansen T.R., Armstrong T.D., Hicklin D.J., Jaffee E.M., Emens L.A. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 2007, 13:3951-3959.
99. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
100. Meyerhardt J.A., Ancukiewicz M., Abrams T.A., Schrag D., Enzinger P.C., Chan J.A., Kulke M.H., Wolpin B.M., Goldstein M., Blaszkowsky L., et al. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS ONE 2012, 7:e38231.
101. Miles D.W., Chan A., Dirix L.Y., Cortés J., Pivot X., Tomczak P., Delozier T., Sohn J.H., Provencher L., Puglisi F., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J.Clin. Oncol. 2010, 28:3239-3247.
102. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N.Engl. J. Med. 2007, 357:2666-2676.
103. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39:61-73.
104. Motz G.T., Santoro S.P., Wang L.P., Garrabrant T., Lastra R.R., Hagemann I.S., Lal P., Feldman M.D., Benencia F., Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 2014, 20:607-615.
105. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N.Engl. J. Med. 2007, 356:115-124.
106. Motzer R.J., Escudier B., Tomczak P., Hutson T.E., Michaelson M.D., Negrier S., Oudard S., Gore M.E., Tarazi J., Hariharan S., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013, 14:552-562.
107. Nasarre P., Thomas M., Kruse K., Helfrich I., Wolter V., Deppermann C., Schadendorf D., Thurston G., Fiedler U., Augustin H.G. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009, 69:1324-1333.
108. Neri D., Supuran C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 2011, 10:767-777.
109. Netti P.A., Roberge S., Boucher Y., Baxter L.T., Jain R.K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc. Res. 1996, 52:27-46.
110. Noman M.Z., Desantis G., Janji B., Hasmim M., Karray S., Dessen P., Bronte V., Chouaib S. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated Tcell activation. J.Exp. Med. 2014, 211:781-790.
111. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
112. Ogino S., Galon J., Fuchs C.S., Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011, 8:711-719.
113. Öhlund D., Elyada E., Tuveson D. Fibroblast heterogeneity in the cancer wound. J.Exp. Med. 2014, 211:1503-1523.
114. Orsenigo F., Giampietro C., Ferrari A., Corada M., Galaup A., Sigismund S., Ristagno G., Maddaluno L., Koh G.Y., Franco D., et al. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability invivo. Nat. Commun. 2012, 3:1208.
115. Özdemir B.C., Pentcheva-Hoang T., Carstens J.L., Zheng X., Wu C.C., Simpson T.R., Laklai H., Sugimoto H., Kahlert C., Novitskiy S.V., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25:719-734.
116. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
117. Palazón A., Aragonés J., Morales-Kastresana A., de Landázuri M.O., Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin. Cancer Res. 2012, 18:1207-1213.
118. Pastuskovas C.V., Mundo E.E., Williams S.P., Nayak T.K., Ho J., Ulufatu S., Clark S., Ross S., Cheng E., Parsons-Reponte K., et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 2012, 11:752-762.
119. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009, 16:196-208.
120. Plotkin S.R., Stemmer-Rachamimov A.O., Barker F.G., Halpin C., Padera T.P., Tyrrell A., Sorensen A.G., Jain R.K., di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N.Engl. J. Med. 2009, 361:358-367.
121. Prowell T.M., Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N.Engl. J. Med. 2012, 366:2438-2441.
122. Ratner M. Next-generation AMD drugs to wed blockbusters. Nat. Biotechnol. 2014, 32:701-702.
123. Raut C.P., Boucher Y., Duda D.G., Morgan J.A., Quek R., Ancukiewicz M., Lahdenranta J., Eder J.P., Demetri G.D., Jain R.K. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS ONE 2012, 7:e26331.
124. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N.Engl. J. Med. 2011, 364:501-513.
125. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J., Archer V., Moore N., Manegold C. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 2010, 21:1804-1809. BO17704 Study Group.
126. Reck M., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., von Pawel J., Gottfried M., Bondarenko I., Liao M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014, 15:143-155. LUME-Lung 1 Study Group.
127. Reis M., Czupalla C.J., Ziegler N., Devraj K., Zinke J., Seidel S., Heck R., Thom S., Macas J., Bockamp E., et al. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J.Exp. Med. 2012, 209:1611-1627.
128. Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo C.F., Sastra S.A., Dekleva E.N., Saunders T., Becerra C.P., Tattersall I.W., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25:735-747.
129. Richeldi L., du Bois R.M., Raghu G., Azuma A., Brown K.K., Costabel U., Cottin V., Flaherty K.R., Hansell D.M., Inoue Y., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N.Engl. J. Med. 2014, 370:2071-2082. INPULSIS Trial Investigators.
130. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., Atkins J.N., Picus J., Czaykowski P., Dutcher J., Small E.J. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J.Clin. Oncol. 2010, 28:2137-2143.
131. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., Perez E.A., Yardley D.A., Chan S.Y., Zhou X., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J.Clin. Oncol. 2011, 29:1252-1260.
132. Roosli C., Linthicum F.H., Cureoglu S., Merchant S.N. Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity. Otol. Neurotol. 2012, 33:473-480.
133. Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T.S., Rivera F., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J.Clin. Oncol. 2008, 26:2013-2019.
134. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N.Engl. J. Med. 2006, 355:2542-2550.
135. Schoors S., De Bock K., Cantelmo A.R., Georgiadou M., Ghesquière B., Cauwenberghs S., Kuchnio A., Wong B.W., Quaegebeur A., Goveia J., et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014, 19:37-48.
136. Seano G., Chiaverina G., Gagliardi P.A., di Blasio L., Puliafito A., Bouvard C., Sessa R., Tarone G., Sorokin L., Helley D., et al. Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nat. Cell Biol. 2014, 16:931-941.
137. Seano G., Daubon T., Genot E., Primo L. Podosomes as novel players in endothelial biology. Eur. J. Cell Biol. 2014, Published online August 7, 2014. 10.1016/j.ejcb.2014.07.009.
138. Semenza G.L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 2014, 9:47-71.
139. Sennino B., Ishiguro-Oonuma T., Wei Y., Naylor R.M., Williamson C.W., Bhagwandin V., Tabruyn S.P., You W.K., Chapman H.A., Christensen J.G., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012, 2:270-287.
140. Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., Yamamoto N., Hida T., Maemondo M., Nakagawa K., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014, 15:1236-1244.
141. Sevick E.M., Jain R.K. Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. Cancer Res. 1989, 49:3513-3519.
142. Shrimali R.K., Yu Z., Theoret M.R., Chinnasamy D., Restifo N.P., Rosenberg S.A. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010, 70:6171-6180.
143. Sitohy B., Nagy J.A., Dvorak H.F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012, 72:1909-1914.
144. Skuli N., Monferran S., Delmas C., Favre G., Bonnet J., Toulas C., Cohen-Jonathan Moyal E. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 2009, 69:3308-3316.
145. Snuderl M., Batista A., Kirkpatrick N.D., Ruiz de Almodovar C., Riedemann L., Walsh E.C., Anolik R., Huang Y., Martin J.D., Kamoun W., et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013, 152:1065-1076.
146. Solano J.M., Bakri S.J., Pulido J.S. Regression of radiation-induced macular edema after systemic bevacizumab. Can. J. Ophthalmol. 2007, 42:748-749.
147. Song J.W., Munn L.L. Fluid forces control endothelial sprouting. Proc. Natl. Acad. Sci. USA 2011, 108:15342-15347.
148. Sorensen A.G., Batchelor T.T., Zhang W.T., Chen P.J., Yeo P., Wang M., Jennings D., Wen P.Y., Lahdenranta J., Ancukiewicz M., et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009, 69:5296-5300.
149. Sorensen A.G., Emblem K.E., Polaskova P., Jennings D., Kim H., Ancukiewicz M., Wang M., Wen P.Y., Ivy P., Batchelor T.T., Jain R.K. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012, 72:402-407.
150. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J.Clin. Oncol. 2010, 28:1061-1068.
151. Stylianopoulos T., Jain R.K. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc. Natl. Acad. Sci. USA 2013, 110:18632-18637.
152. Stylianopoulos T., Martin J.D., Chauhan V.P., Jain S.R., Diop-Frimpong B., Bardeesy N., Smith B.L., Ferrone C.R., Hornicek F.J., Boucher Y., et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. USA 2012, 109:15101-15108.
153. Suzuki H., Fukuhara M., Yamaura T., Mutoh S., Okabe N., Yaginuma H., Hasegawa T., Yonechi A., Osugi J., Hoshino M., et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J.Transl. Med. 2013, 11:97.
154. Tewari K.S., Sill M.W., Long H.J., Penson R.T., Huang H., Ramondetta L.M., Landrum L.M., Oaknin A., Reid T.J., Leitao M.M., et al. Improved survival with bevacizumab in advanced cervical cancer. N.Engl. J. Med. 2014, 370:734-743.
155. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N.Engl. J. Med. 2009, 360:563-572.
156. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
157. Tse J.M., Cheng G., Tyrrell J.A., Wilcox-Adelman S.A., Boucher Y., Jain R.K., Munn L.L. Mechanical compression drives cancer cells toward invasive phenotype. Proc. Natl. Acad. Sci. USA 2012, 109:911-916.
158. Vakoc B.J., Lanning R.M., Tyrrell J.A., Padera T.P., Bartlett L.A., Stylianopoulos T., Munn L.L., Tearney G.J., Fukumura D., Jain R.K., Bouma B.E. Three-dimensional microscopy of the tumor microenvironment invivo using optical frequency domain imaging. Nat. Med. 2009, 15:1219-1223.
159. van Beijnum J.R., Dings R.P., van der Linden E., Zwaans B.M., Ramaekers F.C., Mayo K.H., Griffioen A.W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108:2339-2348.
160. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausová J., Macarulla T., Ruff P., van Hazel G.A., Moiseyenko V., Ferry D., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J.Clin. Oncol. 2012, 30:3499-3506.
161. van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G., Schöffski P., Aglietta M., Staddon A.P., Beppu Y., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886. EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study groupPALETTE study group.
162. Van der Veldt A.A., Lubberink M., Bahce I., Walraven M., de Boer M.P., Greuter H.N., Hendrikse N.H., Eriksson J., Windhorst A.D., Postmus P.E., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012, 21:82-91.
163. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
164. Vasudev N.S., Reynolds A.R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014, 17:471-494.
165. Végran F., Boidot R., Michiels C., Sonveaux P., Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011, 71:2550-2560.
166. Wang W., Ma Y., Li J., Shi H.S., Wang L.Q., Guo F.C., Zhang J., Li D., Mo B.H., Wen F., et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther. 2013, 20:970-978.
167. Wells S.A., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., Baudin E., Elisei R., Jarzab B., Vasselli J.R., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J.Clin. Oncol. 2012, 30:134-141.
168. Wilke H., Muro K., Van Cutsem E., Oh S.C., Bodoky G., Shimada Y., Hironaka S., Sugimoto N., Lipatov O., Kim T.-Y., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014, 15:1224-1235. RAINBOW Study Group.
169. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10:145-147.
170. Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D.V., Lahdenranta J., Chung D.C., Fischman A.J., Lauwers G.Y., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J.Clin. Oncol. 2009, 27:3020-3026.
171. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
172. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
173. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N.Engl. J. Med. 2013, 369:122-133.
174. Yasuda S., Sho M., Yamato I., Yoshiji H., Wakatsuki K., Nishiwada S., Yagita H., Nakajima Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect invivo. Clin. Exp. Immunol. 2013, 172:500-506.
175. You W.K., Sennino B., Williamson C.W., Falcón B., Hashizume H., Yao L.C., Aftab D.T., McDonald D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71:4758-4768.
176. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 1996, 93:14765-14770.
177. Zhang X., Gaspard J.P., Chung D.C. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001, 61:6050-6054.
178. Zhang J., O'Carroll S.J., Henare K., Ching L.M., Ormonde S., Nicholson L.F., Danesh-Meyer H.V., Green C.R. Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy. FEBS Lett. 2014, 588:1365-1371.
179. Zhou Z., Doi M., Wang J., Cao R., Liu B., Chan K.M., Kortesmaa J., Sorokin L., Cao Y., Tryggvason K. Deletion of laminin-8 results in increased tumor neovascularization and metastasis in mice. Cancer Res. 2004, 64:4059-4063.
180. Zhu A.X., Ancukiewicz M., Supko J.G., Sahani D.V., Blaszkowsky L.S., Meyerhardt J.A., Abrams T.A., McCleary N.J., Bhargava P., Muzikansky A., et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin. Cancer Res. 2013, 19:1557-1566.